RT Journal Article
T1 Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT.
A1 Herrera-Hidalgo, Laura
A1 Luque-Marquez, Rafael
A1 de Alarcon, Aristides
A1 Guisado-Gil, Ana Belen
A1 Gutierrez-Gutierrez, Belen
A1 Navarro-Amuedo, Maria Dolores
A1 Praena-Segovia, Julia
A1 Carmona-Caballero, Juan Manuel
A1 Fraile-Ramos, Elena
A1 Gutierrez-Valencia, Alicia
A1 Lopez-Cortes, Luis Eduardo
A1 Gil-Navarro, Maria Victoria
K1 MSSA
K1 OPAT
K1 cefazolin
K1 home-delivery
K1 methicillin-susceptible Staphylococcus aureus
AB Cefazolin is a recommended treatment for methicillin-susceptible Staphylococcus aureus (MSSA) infections that has been successfully used in outpatient parenteral antibiotic therapy (OPAT) programs. The aim of this study was to assess the clinical outcomes of cefazolin delivered each day (Group 24) vs. every two days (Group 48) for MSSA infections in OPAT programs. It was a prospective observational study with retrospective analysis of a cohort of MSSA infections attended in OPAT. The primary outcome was treatment success, defined as completing the antimicrobial regimen without death, treatment discontinuation, or readmission during treatment and follow-up. A univariate and multivariate logistic regression model was built. A two-sided p < 0.05 was considered statistically significant. Of the 149 MSSA infections treated with cefazolin 2 g/8 h in OPATs, 94 and 55 patients were included in the delivery Group 24 and Group 48, respectively. Treatment failure and unplanned readmission rates were similar in both groups (11.7% vs. 7.3% p = 0.752 and 8.5% vs. 5.5% p = 0.491). There was a significant increase in vascular access complications in Group 24 (33.0%) with respect to Group 48 (7.3%) (p < 0.001). Treating uncomplicated MSSA infection with cefazolin home-delivered every two days through an OPAT program is not associated with an increased risk of treatment failure and entails a significant reduction in resource consumption compared to daily delivery.
PB MDPI AG
SN 2077-0383
YR 2022
FD 2022-03-11
LK http://hdl.handle.net/10668/21255
UL http://hdl.handle.net/10668/21255
LA en
NO Herrera-Hidalgo L, Luque-Márquez R, de Alarcon A, Guisado-Gil AB, Gutierrez-Gutierrez B, Navarro-Amuedo MD, et al. Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT. J Clin Med. 2022 Mar 11;11(6):1551.
DS RISalud
RD Apr 8, 2025